Valeant reports strong 48-week data for Infergen
The USA's Valeant Pharmaceuticals presented encouraging 48-week data from a trial of its hepatitis C drug Infergen (interferon alfacon 1). Findings from the DIRECT trial were reported at the American Association for the Study of Liver Diseases annual meeting, held in Boston.
The ongoing study is evaluating the daily use of Infergen in combination with Roche's Copegus (ribavirin) for the treatment of HCV in patients who were non-responsive to previous pegylated interferon and ribavirin therapy.
The percentage of patients who were virus-negative at end-of-treatment (week 48) for the Infergen 9mcg and 15mcg groups were 16% and 19%, respectively, according to the transcription-mediated amplification assay, while response rates using the bDNA assay were 22% and 25%, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze